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Leishmania promastigotes express several prominent glycoconjugates, either secreted or anchored to the parasite surface. Of these
lipophosphoglycan (LPG) is the most abundant, and along with other phosphoglycan-bearing molecules, plays important roles in
parasite infectivity and pathogenesis in both the sand ﬂy and the mammalian host. Besides its contribution for parasite survival
in the sand ﬂy vector, LPG is important for modulation the host immune responses to favor the establishment of mammalian
infection. This review will summarize the current knowledge regarding the role of LPG in Leishmania infectivity, focusing on the
interaction of LPG and innate immune cells and in the subversion of mammalian functions by this molecule.
1.Introduction:Leishmania
andLipophosphoglycan
Leishmaniasisiscausedbyinfectionwithprotozoanparasites
of the Trypanosomatid genus Leishmania. The disease is
endemic in several regions, including west Asia, Africa, and
South America. In humans, several disease manifestations
have been observed, ranging from self-healing cutaneous
lesions to progressive and fatal systemic infection [1]. Leish-
maniasisistransmittedbythebiteofphlebotominesandﬂies
and in most parts of the world is a zoonosis, although in
some areas direct human-ﬂy-human transmission has been
reported [1].
T h el i f ec y c l eo fLeishmania has two main morpholog-
ical forms: ﬂagellated promastigotes, which replicate and
develop in the midgut of the sand ﬂy vector, and rounded
amastigotes, which live and multiply inside the macrophages
of the vertebrate host. The establishment of the infection
begins with the inoculation by the sand ﬂy vector’s bite
of metacyclic promastigotes into the vertebrate host. From
this wound site, the parasites encounter a variety of cell
types including neutrophils, Langerhans and dendritic cells,
keratinocytes, and tissue macrophages, all of which have
been proposed to serve as the “ﬁrst contact” host cell
(reviewed in [2]). While in vitro and in some cases in
vivo studies provide good support for these models, the
complex nature of the sand ﬂy bite makes it diﬃcult to
ascertain the quantitative importance of these to the ﬁnal
parasitic outcome. Ultimately, the metacyclic forms of the
parasite are internalized and diﬀerentiate intracellularly to
the amastigote form. In macrophages, amastigotes multiply
inside the acidic vacuoles, and eventually are released after
lysis, spreading the infection to uninfected cells [3]. Current
knowledge about the steps leading to parasite escape is
limited, for example, whether it is regulated by the parasite
or occurs simply through overwhelming the capacity of the
macrophage to harbor them.
Leishmania promastigotes are covered by a thick glyco-
calyx comprised of abundant glycoconjugates important for
parasite survival and pathogenesis. These molecules include
Lipophosphoglycan (LPG), proteophosphoglycan (PPG),
gp63metalloproteinase,andglycophosphatidylinositollipids
(GIPLs). One notable feature distinguishing the Leishmania
surface from that of the host is that most parasite molecules
are linked to the parasite surface through glycosylphos-
phatidylinositol (GPI) lipid anchors [4–8]. Leishmania also2 Journal of Parasitology Research
secrete protein-linked phosphoglycans (PGs), such as the
secreted proteophosphoglycan (sPPG) and secreted acid
phosphatase (sAP) [9].
LPG is the most abundant glycoconjugate on the surface
of Leishmania promastigotes. The GPI anchor which links
LPG at surface of the parasite is constituted by a 1-O-
alkyl-2-lyso-phosphatidyl(myo)inositol lipid anchor with a
heptasaccharide glycan core, to which is joined a long PG
polymer composed of 15–30 [6-Gal(β1,4)Man(α1)-PO4−]
repeating units, and terminated by a capping oligosaccharide
(Figure 1). The PG repeating units are often modiﬁed by
other sugars, which are typically species and stage speciﬁc.
Procyclic and metacyclic promastigotes of all Leishmania
species express high amounts of LPG on their surface, in
contrast to amastigotes, whose LPG expression is highly
downregulated [10]. In promastigotes, LPG plays an impor-
tant role for parasite survival inside sand ﬂy vector and for
macrophage infection, as discussed below. In contrast, the
survival of amastigotes inside host macrophages is improved
by other PG-containing glycoconjugates, such as PPG, which
are highly expressed on its surface. All of the LPG domains
are shared with other parasite surface molecules, to varying
extents and degrees of relatedness. The PG repeat, side
chains, and caps can be found on PPG or sAP, and both the
GPI glycan core and lipid anchor have similarities with those
presentinbothGIPLsandGPI-anchoredproteins[8,11,12].
As described below, the usual of mutants defective in speciﬁc
steps of LPG biosynthesis have proven useful in resolving the
roleofLPGdomainsclearlyfromrelatedonesbornebyother
molecules.
2. The Role(s) of LPG andPGsin
the Sand Fly Vector
A number of obstacles present in the sand ﬂy vector digestive
tract are potentially able to impair the development of Leish-
mania, including digestive enzymes, the midgut peritrophic
membrane barrier, avoidance of excretion along with the
digested blood meal, and the anatomy and physiology of
the anterior gut (Figure 2) .T h e s eb a r r i e r sh a v ep r o v i d e dt h e
evolutionarydriveforexpressionofmoleculesbytheparasite
required for successful development in the sand ﬂy vector. As
in the mammalian stages emphasized in later sections, LPG
and related PGs are key molecules important for survival
inside the hostile environment of sand ﬂy vector [9].
During the digestion of blood meal in the insect midgut,
the intracellular amastigotes initiate their diﬀerentiation
to the motile procyclic promastigotes. These forms of the
parasite leave the macrophages and are exposed to the hostile
environment of the midgut. The dense glycocalyx formed
by LPG and PPG provides protection against the action of
midgut hydrolytic enzymes and by inhibiting the release of
midgut proteases [13]. Procyclic promastigotes are able to
attach to midgut epithelial cells, which enable the parasite
to be retained within the gut during excretion of the digested
blood meal. Several ﬁndings have suggested that LPG plays
an important role in attachment of promastigotes in midgut
in some species or strains such as the L. major Friedlin
line [14–16], which binds to the sand ﬂy midgut lectin
PpGalec [17]. However, in other species, LPG appears to
play less of a role in attachment, as LPG-deﬁcient mutants
retain the ability to bind [18, 19]. The molecules mediating
this attachment are unknown although a role for parasite
lectins has been suggested [20, 21]. For those strains/species
dependent upon LPG for binding, the parasite must then
ﬁnd a way to release from the midgut in order to be free
for subsequent transmission. To do this, metacyclic parasites
synthesize an LPG unable to interact with host lectins. For L.
major strain Friedlin, the procyclic Gal-β 1–3 PGs of LPG
are“capped” with D-arabinopyranose, resulting in an LPG
unable to bind PpGalec [17, 22]. In contrast, in L. donovani
which synthesizes an LPG lacking PG modiﬁcations, binding
through the terminal capping sugar is “masked” through
elongation of the LPG chain [23].
The promastigote stage of many Leishmania species elab-
orates a thick mucoid “plug” during infections, comprised
primarily of PPGs along with other shed parasite molecules.
At the time of transmission by biting, the plug contents
are inoculated along with parasites and saliva into the host.
Seminal studies by Bates and collaborators have suggested
that the PG repeats borne on PPGs within the plug play
key roles in exacerbating the subsequent infections in L.
mexicana, thereby implicating PGs synthesized and secreted
by Leishmania in the ﬂy as important immunomodulators
of the host response [24, 25] .N o t a b l ys a n dﬂ ys a l i v a
can exacerbate Leishmania infections as well. It is worth
pointing out that most experimental studies of Leishmania
transmission are compromised to some extent by the use
of needle inoculated parasites, lacking these key biological
mediators as well as diﬀering in the amount of local tissue
damage.
3.The Role(s) of LPGandRelated PGsin
Mammalian Infectivity
As seen with the sand ﬂy stages, LPG and related PGs
have been implicated in a variety of key steps required
for infectivity of mammalian hosts (Figure 2). Here, we
summarize the current information regarding the role of
LPG for subversion of mammalian protective responses by
the parasite, and the recognition of parasite LPG by the
mammalian innate immune cells.
4. The Role of LPG for Avoidance of
Lysisby Complement
Before the internalization by host cells, metacyclic pro-
mastigotes must evade lysis by the mammalian complement
system. Several studies using puriﬁed LPG or LPG-deﬁcient
parasites have shown that this molecule defends against
complement-mediated lysis [26, 27]. L. major metacyclic
promastigotes,theinfectiveformsformammals,areresistant
to complement-mediated lysis while the procyclic forms,
which reside inside the sand ﬂy vector, are highly susceptible
[28]. This diﬀerence is conferred by changes in the length of
the metacyclic LPG PG polymer domain, which bears aboutJournal of Parasitology Research 3
P P
P
P
OH O
Man
α2
Cap
Phosphoglycan
repeating units Glycan core
Lyso-alkyl
phosphatidyl
inositol anchor
β4Manα -[6 β4Manα ] - α6 α3 β3Manα3Manα4GNα6
Glc
α6
6
15−−30 Gal Gal Gal Gal Galf
Figure 1: Structure of Lipophosphoglycan from Leishmania donovani. The four key domains (cap, phosphoglycan repeating units,
glycan core and lipid anchor) are discussed further in the text. The number of phosphoglycan (PG) repeating units increases during
metacyclogenesis, contributing to the role of LPG in complement resistance. In many Leishmania species, side chain modiﬁcations of the
PG Gal residue are common, where they can play a role in sand ﬂy transmission. The structure of the cap also diﬀers amongst species. Gal,
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Figure 2: Role of LPG in Leishmania infectivity and virulence. Shown are putative and bona ﬁde actions of Leishmania spp. LPG molecules
in subversion of host and vector functions. These LPG functions include (1) physical protection to promastigotes against hydrolytic enzymes
in the digestive tract of insect; (2) attachment of promastigotes to the gut wall; (3) In the mammalian host, promastigotes protection against
lysis by complement proteins; (4) attachment of parasites to the macrophage membranes or alternative transiently infected cells, such as
neutrophils, dendritic cells and perhaps others; (5) transient impairment of the phagosome maturation; (6) physical protection against
degradation by lysosomal enzymes; (7) modulation of macrophages activation through impairing the synthesis of nitrogen species and
cytokines related to the control of infection and protection from ROS.
twice as many repeating units as the procyclic promastigotes.
This prevents the attachment of complement membrane
attack complex (MAC) and pore formation on parasite
surface [28]. However, earlier steps in the complement
cascade may contribute in the entrance of Leishmania into
macrophages through complement receptors. LPG, together
with the protease gp63, is able to activate the complement
system, leading to the generation of the C3b and C3bi
opsonins. C3b and C3bi thus bind to Leishmania surface and
mediate the parasite phagocytosis by complement receptor
(CR) 1 and CR3 [29–35]. Phagocytosis of Leishmania via
CR1 and CR3 receptors is considered as a means of “silent
entry” into macrophages, because it does not prompt the
oxidative burst and impairs the production of IL-12 [32, 36–
38]. However, infections of CR3-deﬁcient mice show very
little attenuation of infection, suggesting that this step may
be of lesser importance or redundant with other binding
interactions in survival [39].4 Journal of Parasitology Research
5. The Role of LPG inParasiteInvasion
andSurvivalinMacrophages
After being inoculated into the mammalian host by the
sand ﬂy vector, the metacyclic promastigotes are internalized
through interactions with a number of diﬀerent receptors.
While at various times interactions with one or another
of these have been presumed or shown to be dominant in
cellularorbiochemicaltests,geneticstudieshavetypicallyled
to conclusions that these interactions typically may instead
be highly redundant in biological settings. In this scenario,
the use of multiple receptors allows the promastigotes to be
quickly internalized by macrophages (reviewed in [40]).
Importantly, the LPG plays an important role as a ligand
during the attachment and invasion process of macrophages,
either directly or indirectly through binding to other pro-
teins.One example is the interaction of LPG with mannose-
fucose receptor expressed by macrophages [41]. In addition,
mannan-binding protein (MBP) is able to bind to mannose
residues on LPG, enabling the formation of C3 convertase
and generation of C3b, which helps promastigotes to attach
to the macrophage as noted above [42]. C-reactive protein
(CRP) binds to LPG of L. donovani metacyclic promastigotes
triggering their phagocytosis by human macrophages via
CRP receptor [43]. Commonly, the engagement of CRP
receptor by its ligand leads to macrophage activation,
resulting in proinﬂammatory cytokine production [44, 45].
However, phagocytosis of L. donovani by CRP receptor leads
to an incomplete activation of macrophages, thus favoring
parasite replication [46].
Following entry, promastigotes are contained in a phago-
some known as parasitophorous vacuole (PV), which under-
goesseveralfusionprocesses,givingrisetoaphagolysosome-
like organelle [47, 48]. During this process, LPG acts to delay
PV fusion with lysosomes, promoting delay in PV acidiﬁ-
cation and acquisition of lysosomal enzymes [49]. Vacuoles
harboring promastigotes of L. donovani and L. major genet-
ically deﬁcient for LPG fuse more extensively and rapidly
with endosomes and lysosomes [27, 50]. While initially
workers postulated that this delay protected promastigotes
from acidic conditions and hydrolytic enzymes until they
had diﬀerentiated to the more acidophilic amastigote stage,
work with LPG-null L. major promastigotes provided little
support for this model [27], as these parasites are able to
survive under several conditions despite rapid fusion with
host lysosomes. Instead, the delay in fusion reﬂects changes
in membrane properties that result in delocalization of the
host oxidative burst from its normal peri-PV location [51].
On top of this, LPG itself is able to interact and deﬂect
oxidants directly [52]. Other roles of the delayed fusion
may not only concern survival but immune recognition and
antigen processing, which is dependent on host hydrolytic
enzymes [50].
Whereas LPG seems to be important to protect Leishma-
nia during diﬀerentiation from promastigote to amastigote
forms, it does not play a signiﬁcant role during the devel-
opment of the amastigote form. Indeed, LPG expression
on amastigotes of several species of Leishmania is highly
downregulated (1000 fold or more) [10] suggesting that
the protective role of LPG is transient and limited to
the beginning of host cell infection. However, other PG-
containing glycoconjugates and especially PPG are expressed
at high levels in amastigotes, and act in PG-dependent
m a n n e rt op r o t e c tt h ea m a s t i g o t e[ 53, 54].
6. The Role of LPG for Inhibition of
MacrophageActivation
Infected macrophages employ several microbicidal mecha-
nisms to eliminate intracellular pathogens. When previously
activated by interferon-gamma (IFN-γ) and tumor necrosis
factor-α (TNF-α) or other microbial components, infected
macrophages express high levels of the inducible nitric
oxide synthase (NOS2), culminating with production of
nitric oxide (NO), NO2
−,a n dN O 3
− [55]. These nitrogen
intermediates coordinate processes that lead to deprivation
ofimportantcomponents,suchasiron,whichleadtorestric-
tionofintracellularparasitesreplication[56].L.major isable
to induce higher amounts of NOS2 in the cutaneous lesion
and draining lymph nodes of the clinically resistant lineage
C57BL/6 compared to the nonhealing BALB/c strain [57].
In addition, mice deﬁcient for NOS2 are more susceptible
to infection with Leishmania, compared to their littermate
controls, as well as macrophages derived from these mice
[58–60]. Thus, the production of NO is indispensable for the
control of L. major infection and for maintaining life-long
control of persisting Leishmania parasites [61–63].
In contrast, infection of unactivated macrophages typi-
cally leads to parasite survival and minimal levels of NOS2-
dependent NO production, to the point that L. major
was referred to as a “stealthy parasite” [64]. Thus, one
of the challenges in experimental models is the need to
distinguish infections where macrophages are naturally or
experimentally activated from those situations where Leish-
mania exhibits successful parasitism and survival. Perusal of
the literature suggests that many workers do not provide
evidence about which fate meets Leishmania under their
experimental infections, which may contribute occasionally
to seemingly contradictory results.
Experimental studies have shown that similar to Leish-
mania, treatment of macrophages with Leishmania glyco-
conjugates can likewise regulate the activation of NOS2 and
production of NO. LPG can synergize with IFN-γ for the
induction of NO expression in murine macrophages in vitro.
However, incubation of macrophages with LPG-derived PG
before stimulation with LPG plus IFN-γ led to inhibition
of NOS2 expression [65]. These studies provided evidence
thattheinteractionbetweenthemacrophageandtheparasite
impairs the activation of the microbicidal mechanisms of
macrophages after exposure to IFN-γ in a process that is
replicated by PG treatments. Given these ﬁndings, it was
surprising that despite the complete absence of LPG or
all PGs in the lpg1− or lpg2− mutants (described further
below), mutant parasites remained “stealthy” and able to
down regulate host cell activation [27, 66]. A similar con-
tradiction was seen in studies of the smaller GIPL, which are
highlyabundantinbothparasitesstagesandhadbeenshownJournal of Parasitology Research 5
to inhibit NO synthesis by macrophage in a dose- and time-
dependent manner, impairing its leishmanicidal activity
[67]. However, mutants defective in the synthesis of the ether
lipidanchorandthuslackingbothLPGandGIPLsresembled
the lpg1− and lpg2− mutants in remaining “stealthy” and
inhibiting host cell activation [68]. This apparent paradox
hasnotbeenresolvedandhasledtoproposalsthatavoidance
of host cell activation may be highly redundant amongst
many parasite surface molecules, perhaps through their
ability to interact with secondary ligands/mediators such as
complement or other serum proteins. One attractive model
is that macrophage deactivation is independent of surface
molecules, instead depending on other processes such as
secretion of parasite molecules through an exosomes-like or
other pathways (reviewed in [69]).
In addition to NO, activated macrophages employ
other antimicrobial molecules, such as ROS or antimicro-
bial peptides, to kill intracellular parasites. ROS such as
superoxide, hydrogen peroxide, and hydroxyl radicals, are
produced after activation of NADPH oxidase and interact
with pathogen phospholipid membranes, inducing damage
a n dd e a do fp a t h o g e n s[ 70]. Some evidence highlights the
importance of ROS in control of Leishmaniagrowth [71, 72].
Upon infection by L. donovani promastigotes, peritoneal
macrophages elicit a strong respiratory burst with release
of superoxide anion, thus favoring the elimination of the
intracellular amastigotes. When infected in the presence
of catalase, an enzyme that catalyze the decomposition of
hydrogen peroxide to water and oxygen, macrophages lost
their ability to kill L. donovani [73]. These results show that
ROSarecentralcompoundsthatacttoeliminateintracellular
Leishmania in vitro.
Respiratory burst activity and NO production are regu-
lated by phosphorylation events mediated by protein kinase
C( P K C )[ 74]. Infection with Leishmania is able to inhibit
PKC activity in macrophages and several ﬁndings suggesting
that LPG is related to this activity, thereby favoring intra-
cellular survival of the parasite through inhibition of both
oxidative burst and NO production [10, 75–79]. Besides
PKC, production of cytokines such as IL-12 was inhibited
in bone marrow-derived macrophages after infection with
L. major [80]. Furthermore, puriﬁed LPG plays similar
inhibitory eﬀect over IL-12 production, probably thought
the activation of the mitogen-activated protein kinase
(MAPK) Erk 1/2, which suppresses IL-12 gene transcription
[81]. Besides IL-12, puriﬁed LPG also suppressed IL-1β gene
expressioninTHP-1monocytesinducedbyendotoxin,TNF-
α or Staphylococcus stimulation [82].
7. Recognition of LPG byMammalian
InnateImmuneReceptors
The initiation of immune response against invading
pathogens starts upon the interaction of microbial molecules
with receptors of innate immune cells. Glycoconjugates
expressed by protozoans interact with macrophage receptors
and are recognized as foreign by immune system. Puriﬁed
GPI-anchored surface proteins of Plasmodium falciparum,
Trypanosoma brucei and L. mexicana, initiate the rapid
activation of macrophage protein tyrosine kinases (PTKs)
[83–85]. GPI anchors expressed by protozoans, such as
Plasmodium and Trypanosoma, can activate the secretion of
cytokines, such as IL-12 and TNF-α, and NO synthesis by
macrophages [83, 85–90].
The activation of Toll-like receptors (TLRs) by micro-
bial ligands recruits the adaptor protein MyD88 (myeloid
diﬀerentiation primary response gene 88) and triggers
intracellular signaling events, culminating on the activation
of the transcription factor NF-κB and its translocation to
nucleus. NF-κB in turn induces innate immune mechanisms
such as the production of reactive oxygen and nitrogen
intermediates, chemokine/cytokine secretion, and cellular
diﬀerentiation [91]. Several evidences have suggested that
Leishmania expresses ligands able to stimulate the TLRs
signaling pathways. RAW macrophages selectively upregu-
lated the IL-1α mRNA expression in response to L. major
infection,andthiswasnotobservedwhenmacrophageswere
transfected with a dominant-negative of MyD88 or when
peritoneal macrophages derived from MyD88-deﬁcient mice
were infected with L. major [92]. In addition, mice deﬁcient
for MyD88 infected with L. major showed an increase in
lesion size compared to their littermate controls [93]. These
results suggest that L. major may express ligands for TLR
activation. Accordingly, L. major LPG activated NF-κB, the
secretion of Th1-type cytokines, ROS, and NO by either
human or murine macrophages in a mechanism dependent
of TLR2 [93–95]. In addition, puriﬁed LPG upregulates
TLR2 expression and stimulate IFN-γ and TNF-α secretion
byhumanNKcellsinaTLR2-dependentmanner[96].Thus,
activation of TLR2 may contribute to host resistance against
Leishmania and LPG is proposed to be a putative agonist for
TLR activation.
In addition to macrophages and NK cells, LPG has been
shown to exert stimulatory eﬀects on dendritic cells (DCs).
Puriﬁed L. mexicana LPG was able to induce the expression
of CD86 and major histocompatibility complex class II
(MHC-II) by DCs; furthermore, L. major LPG stimulated
the expression of CD25, CD31, and vascular-endothelial
cadherin by mouse Langerhans cells, albeit accompanied by
inhibition of their migratory activity [97, 98]. Importantly,
upregulation of stimulatory and costimulatory molecules in
DCs occurs in response to activation of pattern recognition
receptors; therefore, these studies corroborate the hypothesis
that that Leishmania LPG triggers activation of these recep-
tors.
Given the interaction of LPG with TLRs in the context of
activatedmacrophageswherethisleadstoaproinﬂammatory
response and parasite control, an important but as yet
unanswered question is how the LPG-TLR interaction fails
to control parasite infection in unactivated macrophages.
A variety of pathways are known which negatively regulate
TLR signaling, and potentially one of these acts to mitigate
TLR activation. A second question is whether LPG or related
molecules are internalized into host cells, which would then
place them in contact with variety internal sensors including
the NOD-like receptors protein family in the cytosol. Early
studies showed LPG traﬃcking into the interior of host cells
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suggesting that Leishmania molecules may gain access to the
host cytosol through some routes, potentially including an
exosome-like pathway [100, 101]. Further work is needed to
conﬁrm these provocative hypotheses and explore the role of
LPG and related glycoconjugates in this process.
8. The Assessment of LPG Functions by
Using LPG-DefectiveMutants
As mentioned above, many studies have used puriﬁed LPG,
fragments thereof, or related molecules, to investigate their
role in Leishmaniapathogenesisandhostresponse.However,
LPG preparations can include contaminating molecules
including proteins, unless proper precautions are taken,
and use of exogenous LPG may not properly mimic the
physiological location and concentrations of LPG delivered
by infecting parasites. Moreover, as noted above, many LPG
domains are shared by other parasite molecules, raising the
possibility that functions attributed to LPG in vitro may
actually be fulﬁlled by LPG-related molecules in vivo.
In the last few years, the generation of LPG mutants
of Leishmania has provided powerful tools to identify the
function of these molecules [102–105]. Of note, the recent
identiﬁcation of genes related to LPG biosynthetic pathways
allowed the generation of “clean” LPG mutant strains by
speciﬁc gene targeting. Leishmania are typically diploid
althoughrecentstudiessuggestthatmanychromosomesmay
be aneuploid, at least transiently [106]. Thus, two or more
successive rounds of gene replacement are required to gener-
a t ef u l lh o m o z y g o u sn u l lm u t a n t s ,a sw h i l ef e a s i b l ei ns o m e
casessexualcrossingremainschallenging[107].Importantly,
the phenotypes of the mutants chosen for biological studies
were rescued by complementation of the speciﬁc LPG gene
into the parasite [108–110]. This rules out the well-known
problem of loss of virulence during transfection or culture
of Leishmania, which occurs sporadically in all species.
Thus far nearly 20 genes aﬀecting various steps of LPG
biosynthesis have been described through complementation
ofLPGmutantsorthroughvariousreversegeneticstrategies.
For the study of virulence, this repertoire of LPG genes
has enabled researchers to concentrate on key mutants that
cleanly aﬀect LPG or related molecules. The ﬁrst genetic
assessment of the role of LPG in parasite virulence and
host immunity followed the identiﬁcation of the LPG1
gene, which was recovered following complementation of
the LPG-deﬁcient R2D2 mutant of L. donovani [110]. This
geneencodesaputativegalactofuranosyltransferaseinvolved
in biosynthesis of the LPG glycan core, but not other
galactofuranosyl-containing glycoconjugates whose synthe-
sis depends on other LPG1-related transferases [111]. lpg1−
mutants of L. major or L. donovani do not express LPG on
their surface, while the expression of other glycoconjugates
remains normal [112, 113], rendering these ideal for studies
of the biological roles mediated exclusively by LPG. lpg1−
mutants are highly susceptible to lysis by complement;
sensitive to oxidative stress, and they fail to even transiently
inhibit phagolysosomal fusion immediately after invasion
[27]. Moreover, L. major lpg1− showed an impaired ability
to survive inside macrophages [27, 113] and in mouse
infections were highly attenuated, as represented by an
extreme delay in lesion progression [27, 113].
Interestingly, the generality of the role of LPG or
even PGs in parasite survival in all Leishmania has been
questioned based on similar genetic studies in L. mexicana,
where a proper lpg1− line shows no decrease in infec-
tivity tests in macrophages or mice [112], although it is
complement sensitive [114]. Despite these observations, the
lpg1−L. mexicana nonetheless showed some alterations in
host response, with a poor ability to stimulate the expression
of costimulatory molecules on mouse DCs, and it was
found that lpg1−L. mexicana-infected mice showed lower
numbers of activated DCs in draining lymph nodes and were
unable to control early parasite burden [97]. Thus, it appears
that LPG plays a quantitatively or qualitatively diﬀerent
role in L. mexicana virulence, especially in directing the
immune response. A similar contrast was found in studies
of an L. mexicana lpg2−, discussed below [115]. Amongst
many potential explanations, the architecture of the PV has
been proposed to be a factor, as it exists as a “spacious,
multiparasite”compartmentinL.mexicanainfectionsversus
a “tight, uniparasitic” compartment in L. major and L.
donovani [114]. Thus, the roles of LPG appear to diﬀer both
quantitatively and qualitative amongst species.
While the LPG-deﬁcient lpg1− parasites show severe
attenuation in both L. donovani and L. major, studies in
the latter species show that some parasites survive and
go on to generate normal amastigotes, in keeping with
the downregulation of LPG during development. Since
other PG-containing glycoconjugates such as PPG are found
throughout the life cycle, the role of the PG moieties gener-
ally was investigated by the use of a mutant globally aﬀecting
PGs. The LPG2 gene was identiﬁed by complementation
of the L. donovani C3PO mutant [109] and was shown in
a series of seminal studies in Turco’s laboratory to encode
the Golgi GDP-mannose transporter [116–118], one of the
founding members of what is now known to be a large
family of nucleoside sugar transporters [119]. LPG2 was also
the ﬁrst multispeciﬁc nucleotide sugar transporters to be
described,beingabletocarrybothGDP-D-Arabinopyranose
and GDP-Fucose in addition to GDP-Man [116]. As noted
earlier, L. major utilizes D-Arabinopyranose as an LPG side
chain “capping” sugar, but neither a role nor glycoconjugates
bearing fucose has been described in Leishmania, although
low levels of GDP-Fuc have been observed in promastigotes
[120].
lpg2− mutant parasites lack all PGs, including LPG
and PPG, but synthesize normal levels of GIPLs and gp63
[66]. L. major and L. donovanI lpg2− mutants failed to
survive in the midgut of sand ﬂy vector and were unable
to establish infection in macrophages. In animal infections,
L. major parasites showed “persistence without pathology,”
with parasites persisting at low levels for the life of infected
animals—a situation reminiscent of the life-long infection
following healing of Leishmania infections in experimental
animals and humans [16, 66, 114]. This parallel was further
extended by the demonstration that as in healed animals, L.
major lpg2− induced long-term immunity against challenge
with a virulent strain of L. major [121]. Observations thatJournal of Parasitology Research 7
lymphocytesisolatedfromL.major lpg2−-infectedmicepro-
ducedlessIL-4andIL-10afterstimulationinvitro,compared
to cells isolated from L. major WT-infected mice, provided
evidences about the anti-inﬂammatory properties of PGs
over immune cells [122]. Importantly, similar eﬀects on
cytokine expression were seen in the lpg5A
−/lpg5B
− double
mutant, which also lacks all PGs, but through inactivation of
Golgi UDP-Gal transporter activity [122, 123]. However, the
lpg5A
−/lpg5B
− mutantshowsavirulencedefectcomparable
to that of the lpg1− rather than lpg2− mutant [123].This
suggests that the “persistence without pathology” phenotype
of the lpg2− mutant may arise from eﬀects on gylcoconju-
gates other than PGs [123]. Thus, comparison amongst the
well-characterized collection of LPG/PG mutants provides a
“genetic sieve”, allowing assignment of the roles of LPG and
PGs separately and in immune interaction fromtheir roles in
generalparasiteinfectivity.Thesestudiesusinglpg2− mutant
parasites provided evidence that PGs, in addition to LPG,
play important roles in Leishmania virulence [122, 123].
9. Concluding Remarks
LPG is a key molecule mediating many important steps
essential for Leishmania virulence, in the hostile environ-
ment of the sand ﬂy vector midgut, or in the mammalian
host. The identiﬁcation of genes related to LPG synthesis
allowed the generation of Leishmania strains defective in
LPG. The uses of these mutants have provided valuable
clues about the role of this glycoconjugate in the biology
of Leishmania. We envisage that further studies using these
and new mutants may elucidate important issues related
to innate immune recognition and host cell activation by
protozoan parasites. This information will greatly increase
our understanding of both Leishmania pathogenesis and the
recognition of protozoan parasites by the mammalian innate
immune system.
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